Aclaris Therapeutics, Inc. Analyst EPS Estimates
Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 3 | -$0.29 | -$0.29 | -$0.29 |
Q2 2024 | 2 | -$0.20 | -$0.20 | -$0.20 |
Q3 2024 | 6 | -$0.01 | $0.02 | -$0.01 |
Q4 2024 | 2 | -$0.16 | -$0.16 | -$0.16 |
Q1 2025 | 5 | -$0.16 | -$0.16 | -$0.16 |
Q2 2025 | 5 | -$0.17 | -$0.17 | -$0.17 |
Q3 2025 | 5 | -$0.16 | -$0.16 | -$0.16 |
Q4 2025 | 5 | -$0.17 | -$0.17 | -$0.17 |
Aclaris Therapeutics, Inc. Earnings Date And Information
Aclaris Therapeutics, Inc. last posted its earnings results on Wednesday, August 7th, 2024. The company reported $-0.15 earnings per share for the quarter, topping analysts' consensus estimates of $-0.19 by $0.04. The company had revenue of 2.77 M for the quarter and had revenue of 31.25 M for the year. Aclaris Therapeutics, Inc. has generated $-1 earnings per share over the last year ($-1.27 diluted earnings per share) and currently has a price-to-earnings ratio of -1.45. Aclaris Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, November 4th, 2024 based on prior year's report dates.
Aclaris Therapeutics, Inc. Earnings History by Quarter
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
08/07/2024 | Q2 2024 | -$0.19 | -$0.15 | 0.04 | $1.82 M | $2.77 M |
05/07/2024 | Q1 2024 | -$0.28 | -$0.24 | 0.04 | $2.40 M | |
02/27/2024 | Q4 2023 | -$0.37 | -$0.02 | 0.35 | $17.57 M | |
11/06/2023 | Q3 2023 | -$0.48 | -$0.41 | 0.07 | $1.57 M | $9.28 M |
08/07/2023 | Q2 2023 | -$0.45 | -$0.42 | 0.03 | $1.90 M | $1.87 M |
05/08/2023 | Q1 2023 | -$0.44 | -$0.39 | 0.05 | $2.53 M | |
02/23/2023 | Q4 2022 | -$0.46 | -$0.50 | -0.04 | $7.75 M | |
11/08/2022 | Q3 2022 | -$0.39 | -$0.32 | 0.07 | $1.60 M | $19.02 M |
08/03/2022 | Q2 2022 | -$0.36 | -$0.25 | 0.11 | $1.53 M | |
05/10/2022 | Q1 2022 | -$0.39 | -$0.28 | 0.11 | $1.45 M | |
02/24/2022 | Q4 2021 | -$0.36 | -$0.37 | -0.01 | $1.79 M | $1.50 M |
11/02/2021 | Q3 2021 | -$0.27 | -$0.35 | -0.08 | $1.77 M | $1.66 M |
08/05/2021 | Q2 2021 | -$0.26 | -$0.34 | -0.08 | $1.75 M | $1.82 M |
05/07/2021 | Q1 2021 | -$0.27 | -$0.57 | -0.3 | $1.78 M | |
02/25/2021 | Q4 2020 | -$0.28 | -$0.30 | -0.02 | $1.39 M | $1.58 M |
11/04/2020 | Q3 2020 | -$0.29 | -$0.25 | 0.04 | $1.47 M | $1.45 M |
08/07/2020 | Q2 2020 | -$0.34 | -$0.28 | 0.06 | $1.23 M | $2.05 M |
05/07/2020 | Q1 2020 | -$0.29 | -$0.37 | -0.08 | $1.41 M | |
02/25/2020 | Q4 2019 | -$0.34 | -$0.45 | -0.11 | $9.80 M | $1.10 M |
11/07/2019 | Q3 2019 | -$0.54 | -$1.34 | -0.8 | $5.92 M | $983,000 |
Aclaris Therapeutics, Inc. Earnings: Frequently Asked Questions
-
When is Aclaris Therapeutics, Inc.'s earnings date?
Aclaris Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, November 4th, 2024 based off last year's report dates.
-
Did Aclaris Therapeutics, Inc. beat their earnings estimates last quarter?
In the previous quarter, Aclaris Therapeutics, Inc. (:ACRS) reported $-0.15 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.19 by $0.04.
-
How can I listen to Aclaris Therapeutics, Inc.'s earnings conference call?
The conference call for Aclaris Therapeutics, Inc.'s latest earnings report can be listened to online.
-
How can I read Aclaris Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Aclaris Therapeutics, Inc.'s latest earnings report can be read online.
-
How much revenue does Aclaris Therapeutics, Inc. generate each year?
Aclaris Therapeutics, Inc. (:ACRS) has a recorded annual revenue of $31.25 M.
-
How much profit does Aclaris Therapeutics, Inc. generate each year?
Aclaris Therapeutics, Inc. (:ACRS) has a recorded net income of $31.25 M. Aclaris Therapeutics, Inc. has generated $-1.27 earnings per share over the last four quarters.
-
What is Aclaris Therapeutics, Inc.'s price-to-earnings ratio?
Aclaris Therapeutics, Inc. (:ACRS) has a price-to-earnings ratio of -1.45 and price/earnings-to-growth ratio is -0.22.